STERIS plc is a global medical technology company specializing in infection prevention, sterilization, and surgical products. The company provides contract sterilization services, capital equipment such as sterilizers and surgical tables, and consumable products to hospitals, pharmaceutical manufacturers, and medical device makers. While legally domiciled in Ireland, STERIS maintains its operational headquarters in Mentor, Ohio.
Financial Statements
In thousands, USD
FY 2026
FY 2025
FY 2024
FY 2023
Total Revenues
5,935,900
5,459,500
5,138,700
4,536,266
Cost of Sales
3,309,400
3,056,800
2,920,500
2,555,540
Gross Profit
2,626,500
2,402,800
2,218,200
1,980,726
Selling, General & Administrative Expenses
1,407,700
1,334,300
1,252,300
1,090,663
Research & Development Expenses
112,900
107,600
103,700
98,477
Other Operating Expenses
4,100
94,200
26,000
485
Operating Profit
1,101,800
866,600
836,100
791,101
Interest and Investment Income
9,800
8,400
11,000
(2,879)
Interest Expense
(60,700)
(86,300)
(144,400)
(107,956)
Non-Operating Income
(3,500)
7,400
—
—
Total Non-Operating Income
(54,400)
(70,500)
(133,400)
(110,835)
Income Before Provision for Income Taxes
1,047,300
796,200
702,800
680,266
Provision for Income Taxes
262,200
184,700
149,500
124,069
Consolidated Net Income
785,100
616,100
380,100
105,813
Net Income Attributable to Minority Interests and Other
2,800
1,400
1,800
(1,217)
Net Income Attributable to Discontinued Operations
—
4,500
(173,200)
(450,384)
Net Income Attributable to Common Shareholders
782,300
614,600
378,200
107,030
Basic EPS
7.97
6.24
3.83
1.07
Diluted EPS
7.93
6.20
3.81
1.07
Basic Weighted Average Shares Outstanding
98,200
98,600
98,800
99,706
Diluted Weighted Average Shares Outstanding
98,700
99,100
99,400
100,246
Shares Outstanding
97,800
98,300
98,900
98,600
FY 2026
FY 2025
FY 2024
FY 2023
Cash and Cash Equivalents
439,600
171,700
207,020
208,357
Total Cash and Cash Equivalents
439,600
171,700
207,020
208,357
Accounts Receivable
1,092,800
1,044,000
1,008,315
864,988
Total Trade Receivables
1,092,800
1,044,000
1,008,315
864,988
Inventories
631,800
581,300
674,535
604,410
Other Current Assets
230,400
203,800
979,253
333,687
Total Current Assets
2,394,600
2,000,800
2,869,123
2,011,442
Net Property, Plant & Equipment
2,316,400
2,112,900
1,938,381
1,799,328
Net Intangible Assets
1,620,000
1,854,400
2,119,282
2,076,699
Goodwill
4,194,800
4,095,700
4,070,712
3,879,219
Other Long-Term Assets
211,400
83,000
66,199
1,055,151
Total Assets
10,737,200
10,146,800
11,063,697
10,821,839
Accounts Payable
338,800
280,800
251,723
264,165
Accrued Expenses
651,600
582,300
498,215
456,972
Short-Term Debt
118,900
125,000
85,938
60,000
Current Portion of Leases
35,800
34,200
31,239
30,065
Other Current Liabilities
—
—
64,012
50,642
Total Current Liabilities
1,145,000
1,022,200
931,127
861,844
Long-Term Debt
1,812,800
1,918,700
3,120,162
3,018,655
Leases
119,600
124,600
145,828
139,557
Other Long-Term Liabilities
462,400
465,600
551,234
714,611
Total Long-Term Liabilities
2,394,800
2,508,900
3,817,224
3,872,823
Total Liabilities
3,540,000
3,531,100
4,748,351
4,734,667
Common Stock
4,280,900
4,420,400
4,543,176
4,486,375
Accumulated Other Comprehensive Income
(113,100)
(292,300)
(328,657)
(320,710)
Retained Earnings
3,015,900
2,475,300
2,087,645
1,911,533
Total Common Shareholders' Equity
7,183,600
6,603,400
6,302,164
6,077,198
Minority Interests and Other
13,600
12,400
13,182
9,974
Total Shareholders' Equity
7,197,200
6,615,800
6,315,346
6,087,172
Total Liabilities and Shareholders' Equity
10,737,200
10,146,800
11,063,697
10,821,839
FY 2026
FY 2025
FY 2024
FY 2023
Net Income
785,100
616,100
380,100
105,813
Depreciation & Amortization
486,500
476,200
565,200
552,897
Share-Based Compensation Expense
61,700
57,400
56,500
38,951
Other Adjustments
(19,200)
(68,100)
117,400
309,309
Changes in Trade Receivables
(25,100)
(28,800)
(128,100)
(133,304)
Changes in Inventories
(24,000)
73,100
(37,500)
(123,921)
Changes in Accounts Payable
51,100
33,600
(19,000)
53,342
Changes in Other Operating Activities
25,100
(11,400)
38,400
(46,140)
Cash from Operating Activities
1,341,400
1,148,100
973,300
756,947
Capital Expenditure
(369,000)
(370,100)
(360,300)
(361,969)
Proceeds from Sale of Property, Plant & Equipment
10,500
9,200
7,400
14,587
Purchases of Investments
(134,000)
(10,800)
(1,500)
—
Proceeds from Sale of Investments
—
—
3,900
—
Payments for Business Acquisitions
(20,100)
(54,100)
(546,300)
(42,572)
Proceeds from Business Divestments
—
814,600
9,500
6,624
Cash from Investing Activities
(512,500)
388,800
(887,400)
(383,330)
Issuance of Short-Term Debt
3,000
(446,300)
181,500
241,657
Net Issuance / (Repayments) of Short-Term Debt
3,000
(446,300)
181,500
241,657
Repayments of Long-Term Debt
(125,000)
(718,100)
(60,000)
(247,875)
Net Issuance / (Repayments) of Long-Term Debt
(125,000)
(718,100)
(60,000)
(247,875)
Issuance of Common Shares
32,900
25,500
10,500
1,828
Repurchases of Common Shares
(235,500)
(211,300)
(11,800)
(308,565)
Net Issuance / (Repurchases) of Common Shares
(202,600)
(185,800)
(1,300)
(306,737)
Common Share Dividends Paid
(241,800)
(219,900)
(200,600)
(183,498)
Other Financing Activities
(1,800)
(2,300)
(4,800)
(2,265)
Cash from Financing Activities
(568,200)
(1,572,400)
(85,200)
(498,718)
Effect of Exchange Rate Changes on Cash and Cash Equivalents
7,200
200
(2,100)
(14,862)
Increase / (Decrease) in Cash, Cash Equivalents and Restricted Cash